ARTICLE | Clinical News
Volibris ambrisentan regulatory update
November 22, 2010 8:00 AM UTC
The European Commission granted Orphan Drug designation for Gilead's Volibris ambrisentan to treat idiopathic pulmonary fibrosis (IPF). The selective endothelin A receptor antagonist is in Phase III ...